MedAire and SENTIO Protect partner for COVID testing with travel certification
MedAire appointed SENTIO’s exclusive partner for their on board molecular testing solution for the superyacht industry…
MedAire, the world’s leading superyacht medical assistance provider and SENTIO Protect, specialist consultants in Covid-19 superyacht response technologies, today announced an important partnership which appoints MedAire as SENTIO’s exclusive partner for their onboard molecular testing solution for the superyacht industry, increasing the options available for vessels in setting up their own onboard testing programme.
Powered by the cue health genetic testing platform, the solution uses molecular NAAT Nucleic Acid Amplification Test (commonly known as PCR) and it only requires a non-invasive, lower nasal swab to test for SARS-CoV-2 presenting results in under 20 minutes, with 99% Sensitivity and 98% Specificity across 4 clinical trials.
The solution also gives superyachts the ability to generate Covid certification for international pre-departure travel without having to leave their vessel, with regulatory approval under U.S. FDA EUA, Health Canada, EU CE IVD Directive and CDSCO India.
In addition it has been successfully validated in detecting the new Omicron Variant of Concern.
Steven Bates, MedAire General Manager, says that “The cue health device and solution is ideal for the superyacht environment, as it is compact and very simple for crew members to learn to use”.
Bates adds that “The device complements MedAire’s existing range of Covid testing options and with low set-up costs, it has already proven an attractive proposition for many of our clients, serving the dual-purpose of mitigating the risk of infection as well as facilitating any required Covid documentation to travel between countries”
James Hammond CEO of the SENTIO Group considers the partnership a perfect fit and envisions the mobile genetic technology taking onboard crew health to another level “Both MedAire and ourselves have a shared vision for greater protection against Covid-19 and the longer term application for monitoring health. We are developing the platform for the maritime sector with the manufacturer and through 2022 there will be additional genetic tests coming online to use with the reader, including other respiratory viruses, cardiac markers, cholesterol, pregnancy and many more.”
To find out more about the solution click here.
The entity that submits this press release to SuperyachtNews.com hereby accepts sole responsibility for the facts, accuracy and completeness of the content. All content and mediums submitted are an acknowledgement of the suitability for publication. SuperyachtNews.com accepts no liability or responsibility for any inaccuracies or errors made by the submitter in this regard.
Click here to become part of The Superyacht Group community, and join us in our mission to make this industry accessible to all, and prosperous for the long-term. We are offering access to the superyacht industry’s most comprehensive and longstanding archive of business-critical information, as well as a comprehensive, real-time superyacht fleet database, for just £10 per month, because we are One Industry with One Mission. Sign up here.